At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Halted 12-12 16:00:00 EST
0.0743
+0.0026
+3.63%
盘后0.0779
+0.0036+4.85%
19:49 EST
High0.0800Low0.0716Vol11.47M
Open0.0790D1 Closing0.0717Amplitude11.72%
Mkt Cap4.46MTradable Cap3.71MTotal Shares59.99M
T/O874.83KT/O Rate22.97%Tradable Shares49.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny
Reuters  ·  12-12 19:32
Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny
Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
THOMSON REUTERS  ·  12-12 19:32
Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Clearmind Medicine Announces 1-for-40 Reverse Stock Split
Reuters  ·  12-11
Clearmind Medicine Announces 1-for-40 Reverse Stock Split
Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
Reuters  ·  12-06
Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing
Reuters  ·  12-03
BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing
BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center
Reuters  ·  12-02
BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center
Clearmind Medicine Advances Cmnd-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/Iia Clinical Trial for Alcohol Use Disorder
THOMSON REUTERS  ·  12-02
Clearmind Medicine Advances Cmnd-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/Iia Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy
Reuters  ·  12-01
Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full Dsmb Approval, and New Elite Site Joins the Clinical Trial
THOMSON REUTERS  ·  12-01
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full Dsmb Approval, and New Elite Site Joins the Clinical Trial
Clearmind Medicine Inc. Announces Date for Upcoming Annual General and Special Meeting of Shareholders
Reuters  ·  11-29
Clearmind Medicine Inc. Announces Date for Upcoming Annual General and Special Meeting of Shareholders
Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading?
Benzinga_recent_news  ·  11-26
Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading?
Clearmind Medicine Kicks-off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/Iia Alcohol Use Disorder Trial
THOMSON REUTERS  ·  11-25
Clearmind Medicine Kicks-off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/Iia Alcohol Use Disorder Trial
Clearmind says DSMB approves continuation of Phase I/IIa trial of CMND-100
TIPRANKS  ·  11-24
Clearmind says DSMB approves continuation of Phase I/IIa trial of CMND-100
Clearmind Medicine Advances CMND-100 Clinical Trial After Positive Safety Review
Reuters  ·  11-24
Clearmind Medicine Advances CMND-100 Clinical Trial After Positive Safety Review
Clearmind Medicine Inc - Dsmb Recommends Continuation of Cmnd-100 Trial
THOMSON REUTERS  ·  11-24
Clearmind Medicine Inc - Dsmb Recommends Continuation of Cmnd-100 Trial
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
GlobeNewswire  ·  11-24
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
Clearmind Medicine Expands FDA-Approved Alcohol Use Disorder Trial to Hadassah Medical Center
Reuters  ·  11-20
Clearmind Medicine Expands FDA-Approved Alcohol Use Disorder Trial to Hadassah Medical Center
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
THOMSON REUTERS  ·  11-20
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
Clearmind Medicine- Entered Securities Purchase Agreement for Purchase & Sale of 10,925,000 of Co’s Common Shares in Registered Direct Offering
THOMSON REUTERS  ·  11-19
Clearmind Medicine- Entered Securities Purchase Agreement for Purchase & Sale of 10,925,000 of Co’s Common Shares in Registered Direct Offering
Clearmind Medicine Reports Positive Early Results for Alcohol Use Disorder Drug in Phase I/IIa Trial
Reuters  ·  11-18
Clearmind Medicine Reports Positive Early Results for Alcohol Use Disorder Drug in Phase I/IIa Trial

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--